CRANFORD, N.J., May 10, 2024
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the
"Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company
dedicated to the development and commercialization of
first-in-class critical care products, today announced its
participation in two upcoming investor conferences. Citius Chairman
and CEO Leonard Mazur will host
one-on-one investor meetings at the EF Hutton Annual Global
Conference on May 15, 2024, and
present and host one-on-one investor meetings at the H.C.
Wainwright BioConnect Investor Conference on May 20, 2024.
EF Hutton Annual Global Conference
Details:
Format:
|
In-person one-on-one
meetings (no general presentations)
|
Location:
|
The Plaza Hotel, New
York City
|
Registration:
|
Visit the
conference website
|
H.C. Wainwright 2nd Annual BioConnect Investor
Conference
Details:
Presentation*:
|
3:30 p.m. ET on Monday,
May 20th; live
streaming available
|
Format:
|
Presentations and
one-on-one meetings
|
Location:
|
Nasdaq Global
Headquarters, New York City
|
Registration:
|
Visit the
conference website
|
*Please note that the presentation date and time are subject to
change. Participants should refer to the final program agenda for
up-to-date information.
About Citius Pharmaceuticals, Inc.
Citius Pharma is a late-stage biopharmaceutical company
dedicated to the development and commercialization of
first-in-class critical care products. The Company's diversified
pipeline includes two late-stage product candidates. At the end of
2023, Citius completed enrollment in a Phase 3 pivotal superiority
trial of Mino-Lok®, an antibiotic lock solution to
salvage catheters in patients with catheter-related bloodstream
infections. The Biologics License Application for LYMPHIR™, a novel
IL-2R immunotherapy for an initial indication in cutaneous T-cell
lymphoma, is currently under review by the FDA with August 13, 2024 assigned as the PDUFA target
action date. Citius previously announced plans to form Citius
Oncology, a standalone publicly traded company with LYMPHIR as its
primary asset. LYMPHIR received orphan drug designation by the FDA
for the treatment of CTCL and PTCL. In addition, Citius completed
enrollment in its Phase 2b trial of
CITI-002 (Halo-Lido), a topical formulation for the relief of
hemorrhoids. For more information, please
visit www.citiuspharma.com.
Investor Contact:
Ilanit
Allen
ir@citiuspharma.com
908-967-6677 x113
View original content to download
multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-upcoming-ef-hutton-and-hc-wainwright-investor-conferences-302141737.html
SOURCE Citius Pharmaceuticals, Inc.